Initial cryoballoon ablation in treatment-naïve AF improves arrhythmia outcomes, symptoms, and quality of life without increasing adverse events compared to antiarrhythmic drugs.
Does an initial treatment strategy of cryoballoon catheter ablation improve arrhythmia outcomes in patients with treatment-naïve atrial fibrillation compared with initial antiarrhythmic drug therapy?
patients with treatment-naïve atrial fibrillation
initial treatment strategy of cryoballoon catheter ablation
initial antiarrhythmic drug therapy
arrhythmia outcomes (freedom from any, or symptomatic atrial tachyarrhythmia)
Cryoballoon ablation is an effective and safe initial rhythm-control strategy for treatment-naïve atrial fibrillation, offering improvements in arrhythmia outcomes and quality of life over antiarrhythmic drugs.
Atrial fibrillation (AF), the most common sustained arrhythmia observed in clinical practice, is a chronic and progressive disorder characterized by exacerbations and remissions. Guidelines recommend antiarrhythmic drugs as the initial therapy for the maintenance of sinus rhythm; however, antiarrhythmic drugs have modest efficacy to maintain sinus rhythm and can be associated with significant adverse effects. An initial treatment strategy of cryoballoon catheter ablation in patients with treatment-naïve AF has been shown to significantly improve arrhythmia outcomes (freedom from any, or symptomatic atrial tachyarrhythmia), produce clinically meaningful improvements in patient-reported outcomes (symptoms and quality of life), and significantly reduce subsequent health care resource use (hospitalization), and it does not increase the risk of serious or any adverse events compared with initial antiarrhythmic drug therapy. These findings are relevant to inform patients, providers, and health care systems regarding the initial choice of rhythm-control therapy in patients with treatment-naïve AF.
“These extremely well-performed, randomized clinical trials have added greatly to our knowledge base and established that—in experienced centers with a good track record of success and low complication rates—ablation can be offered to selected patients as initial therapy for paroxysmal atrial fibrillation.”
Building similarity graph...
Analyzing shared references across papers
Jason G. Andrade
Oussama M. Wazni
Malte Kuniss
Journal of the American College of Cardiology
University of British Columbia
Cleveland Clinic
Université de Montréal
Building similarity graph...
Analyzing shared references across papers
Andrade et al. (Sun,) conducted a review in Atrial fibrillation. Cryoballoon catheter ablation vs. Antiarrhythmic drug therapy was evaluated on Arrhythmia outcomes (freedom from any, or symptomatic atrial tachyarrhythmia). Initial cryoballoon ablation in treatment-naïve AF improves arrhythmia outcomes, symptoms, and quality of life without increasing adverse events compared to antiarrhythmic drugs.
www.synapsesocial.com/papers/69e795628a4862ceef5c8dc4 — DOI: https://doi.org/10.1016/j.jacc.2021.06.038
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: